EGFR and neoplasm: The BENEFIT study by Wang et al. [8] showed a median PFS of 13.2 months in patients with EGFR-sensitizing mutations only, versus 9.3 months in patients with EGFR-concomitant tumor-suppressor-gene mutations and only 4.6 months in those with EGFR-concomitant oncogene mutations.